AstraZeneca’s Ultomiris has been approved by the FDA for the treatment of neurological disorders in the past. However, it has once again been acclaimed for the treatment of myasthenia gravis (gMG), a neuromuscular disorder that affects muscle functioning and causes extreme weakness. Initially, Ultomiris was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. Experts believe that Ultomiris can be expected to give a tough time to Soliris as it costs less and has to be infused every eight weeks, contrary to Soliris which has to be infused every two weeks.
Read More from FiercePharma
English